NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
72 trialsNCT05554341 2026-03-18
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05554380 2026-03-18
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT04449549 2026-03-09
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05283226 2026-01-23
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NATCO Pharma Ltd.
Phase 2 Recruiting
NCT07346196 2026-01-20
A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck
University of Chicago
Phase 2 Not yet recruiting
NCT05112965 2026-01-07
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06320405 2025-12-29
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
OHSU Knight Cancer Institute
Phase 1/2 Recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT06246110 2025-11-12
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Eikon Therapeutics
Phase 2 Recruiting
NCT01187199 2025-10-27
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03564691 2025-10-07
MK-4830-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT05407675 2025-10-03
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04879368 2025-07-17
INTEGRATEIIb
Australasian Gastro-Intestinal Trials Group
Phase 3 Active not recruiting
NCT06904300 2025-06-05
Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT03719924 2025-01-08
OESIRI
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT02794571 2024-12-05
Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT03873883 2024-09-19
IO-001
iTeos Therapeutics
Phase 1 Completed
NCT03292822 2024-06-20
Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line
Cairo University
Phase 1 Completed
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02317874 2023-08-29
Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT02761694 2023-05-06
MK-4440-001
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT01015222 2022-11-23
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03665441 2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3 Completed
NCT05552807 2022-09-23
SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sinocelltech Ltd.
Phase 1 Unknown
NCT05467189 2022-07-20
Antineoplastic Drugs in Elderly Patients
Shandong University
Recruiting
NCT02630199 2022-06-15
Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer
Samsung Medical Center
Phase 1 Completed
NCT05241132 2022-02-15
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT01362374 2022-01-12
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01968915 2020-12-19
Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01285466 2020-12-09
A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab
Novartis
Phase 1 Completed
NCT01633970 2020-10-08
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01653470 2020-01-28
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT03057366 2019-11-18
A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT00848718 2019-11-12
MK-2206-003
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01868022 2019-08-19
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
GlaxoSmithKline
Phase 1 Completed
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT03636685 2018-08-17
Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC
ChineseAMS
Phase 1/2 Unknown
NCT01653912 2018-04-02
Dose-finding Study in Platinum-Resistant Ovarian Cancer
Accenture
Phase 1/2 Completed
NCT01411410 2017-10-11
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer
Bayer
Phase 1 Completed
NCT02240212 2017-04-11
Study of Afuresertib Combined With Paclitaxel in Gastric Cancer
Novartis
Phase 1 Completed
NCT00607048 2017-03-27
Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT00936702 2017-03-21
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01497470 2016-10-10
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
Achieve Life Sciences
Phase 1 Completed
NCT00201734 2016-09-23
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
Ohio State University Comprehensive Cancer Center
Phase 1/2 Terminated
NCT00737243 2016-08-17
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00422682 2016-06-10
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
Sanofi
Phase 1 Completed